Senior Director Clinical Pharmacology
Bayer
Bonnie received her B.S. and Pharm.D. from Rutgers University in 2003 and then completed a post-doctoral fellowship in clinical pharmacology at Roche, after which she joined the Roche Clinical Pharmacology Department. She has been responsible for leading the clinical pharmacology strategy for several projects in the Infectious Diseases and Oncology therapeutic areas including implementing model-based strategies to optimize dosing regimens for Pegasys/Copegus and Tamiflu in sensitive populations; designing an extensive clinical pharmacology program for danoprevir/ritonavir, an HCV protease inhibitor, ultimately supporting its approval in China. In the Oncology group, she led the clinical pharmacology strategy and collaborated with cross-functional colleagues on early model informed drug development (MIDD) plans for several EIH/phase 1-stage small molecule and BsAb oncology projects, including leading a translational sub-team utilizing MIDD to optimize the dosing regimen for a novel epigenetic compound.
In 2014 Bonnie became the Oncology Clinical Pharmacology Section Head, responsible for line management and project oversight of early and late stage oncology projects for the NY-based Clinical Pharmacology team. In 2016 she took the role of NY Site Head for the Pharmaceutical Sciences Department and became a member of the Clinical Pharmacology Leadership Team and NY Site Leadership Team. During this time Bonnie worked on several site-based initiatives including various interactions with the NYC Biotech community, facilitating interactions with Flatiron on the use of real-world evidence and leading a plenary session on tumor agnostic drug development at a global symposium to highlight NY-based contributions to the entrectinib development program. In 2019, Bonnie moved to Bayer and is leading the clinical pharmacology programs for BAY 2927088 and regorafenib.